--- title: Sign-up for AmacaThera's newsletter description: Sign-up for AmacaThera's newsletter and see what kind of updates you can expect from us. --- [![newsletter-signup-v2](https://7850637.fs1.hubspotusercontent-na1.net/hub/7850637/hubfs/newsletter-signup-v2.jpg?width=980&height=300&name=newsletter-signup-v2.jpg "newsletter-signup-v2")](http://newsletter.amacathera.ca/?hsLang=en) # Stay in the loop You'll receive quarterly updates on our progress. ## What kind of updates can I expect? ### Here are a few recent stories you may have missed.  ![needles](https://7850637.fs1.hubspotusercontent-na1.net/hub/7850637/hubfs/needles.jpg?width=600&height=435&name=needles.jpg "needles") ### AmacaThera's $10.3 M Series A In February, 2021, we closed an oversubscribed Series A led by Lumira Ventures. Read more about this [funding round](https://www.amacathera.ca/about/news/amacathera-announces-close-of-oversubscribed-series-a-financing-to-advance-a-novel-post-operative-nonopioid-pain-therapy-in-clinical-trials).  ![news-molly](https://7850637.fs1.hubspotusercontent-na1.net/hub/7850637/hubfs/news-molly.jpg?width=600&height=435&name=news-molly.jpg "news-molly") ### Out of the lab, into the marketplace CEO Dr. Michael J. Cooke's and Chief Science Officer Dr. Molly Shoichet were [featured in the *Globe and Mail*](https://www.amacathera.ca/about/news/out-of-the-lab-into-the-marketplace-how-one-of-canadas-most-celebrated-scientists-molly-shoichet-is-bringing-her-key-discovery-to-market).  ![incision](https://7850637.fs1.hubspotusercontent-na1.net/hub/7850637/hubfs/incision.jpg?width=600&height=435&name=incision.jpg "incision") ### What is AMT-143? In July 2020, AmacaThera received approval from Health Canada for AMT-143 to proceed into Phase I clinical trials. Learn about [our technology](https://www.amacathera.ca/technology/amt-143/).  [mailto:info@amacathera.ca](mailto:info@amacathera.ca)